Skip to Content
Webinar Recording

Tislelizumab-jsgr: A Unique PD-1 Inhibitor

Recorded on: April 15, 2025

 

 

Discover how tislelizumab is shaping the treatment landscape for advanced or metastatic esophageal squamous cell carcinoma (ESCC) and gastric/gastroesophageal junction (G/GEJ) adenocarcinoma.

 

Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC from Minnesota Oncology will break down:

  • The mechanism of action and therapeutic role of tislelizumab
  • Key findings from the RATIONALE 302 and 305 trials, supporting its use in both previously treated and first-line settings

  • Biomarker considerations and patient selection strategies for optimal outcomes

  • Recommended dosing and administration protocols, including management of immune-mediated adverse events

  • myBeOne Support™, a patient support program designed to enhance access, adherence, and outcomes

 

If you have any questions or would like to request the meeting invite, contact Jonathan Rivera.